Sildenafil Oral

Therefore, inhibitors of these isoenzym)8.5 (es )]TJ 0.001 Tc -0.001 Tw 0 -1.165 TD [(m)8.8 (ay reduce sildenafil clearance.

What should I know about storage and disposal of this medication?

Dosage for erectile dysfunction (ED)

)]TJ 0 Tc 0 Tw T* ( )Tj /TT2 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.18 TD (In vivo)Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw 2.865 0 Td ( studies:)Tj /TT0 1 Tf 3.535 0 Td [( Cim)8.5 (etidine \(800 m)8.5 (g)0.7 (\), a nonspecific CYP inhibitor, caused a 56% increase in )]TJ -6.4 -1.165 Td [(plasm)8.4 (a)-0.6 ( sildenafil concentrations when coadm)8.4 (i)-1.6 (nistered with VIAGRA \(50 m)8.4 (g)0.6 (\) to healthy )]TJ 0.0009 Tc 0 Tw 0 -1.165 TD (volunteers. )Tj 0 Tc T* ( )Tj 0.0001 Tc -0.0001 Tw T* [(W)8.9 (hen a single 100 m)7.9 (g dose of VIAGRA was adm)7.9 (i)]TJ 0.0008 Tc -0.0008 Tw 20.335 0 Td [(nistered with erythrom)8.6 (ycin, a specific )]TJ 0.0007 Tc -0.0007 Tw -20.335 -1.165 Td [(CYP3A4 inhibitor, at steady state \(500 m)8.5 (g)0.7 ( bid for 5 days\), there was a 182% increase in )]TJ T* [(sildenafil system)8.5 (ic exposure \(AUC\). In addition, in a study perform)8.5 (ed in healthy m)8.5 (ale )]TJ T* [(volunteers, coadm)8.5 (i)-1.5 (nistration of the HIV protease i)-1.1 (nhibitor saquinavir, also a CYP3A4 inhibitor, )]TJ T* [(at steady state \(1200 m)8.5 (g)0.7 ( tid\) with VIAGRA \(100 m)8.5 (g)0.7 ( single dose\) resulted in a 140% increase in )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 312 0 obj <>>>/Resources 325 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 313 0 obj <>>>/Resources 327 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 327 0 obj <> endobj 328 0 obj <> endobj 326 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 325 0 obj <> endobj 329 0 obj <> endobj 324 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 311 0 obj <> endobj 306 0 obj <>stream q 1 0 0 1 -8.008606 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.008606 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.9914 47.6228 Tm ( )Tj 19 -0.005 Td (12)Tj 0.0008 Tc -0.0008 Tw -19 54.94 Td [(- In those patients already taking an optim)8.6 (ized dose of a PDE5 inhibitor, alpha-blocker therapy )]TJ 0 -1.165 TD [(should be initiated at the lowest dose. Stepwise increase in alpha-block\ er dose m)8.6 (ay be associated )]TJ 0.0005 Tc -0.0005 Tw T* (with further lowering of blood pressure when taking a PDE5 inhibitor.

• Following a healthy lifestyle can improve treatment outcomes.
• It’s important to confirm a diagnosis before starting sildenafil.
• Side effect severity can depend on dosage and individual factors.
• A doctor may adjust doses based on patient response.

)Tj T* [(- Safety of com)8.3 (b)0.5 (ined use of PDE5 inhibitors and alpha-blockers m)8.3 (a)-0.7 (y be affected by other )]TJ 0.0009 Tc -0.0009 Tw T* [(variables, including intravascular volum)8.7 (e depletion and other anti-hypertensive drugs.

)]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Viagra has system)8.5 (ic vasodilatory properties and m)8.5 (ay augm)8.5 (ent the blood pressure lowering effect )]TJ 0.0009 Tc -0.0009 Tw sildenafil tables T* [(of other anti-hypertensive m)8.7 (edications. )]TJ 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(Patients on m)8.8 (u)1 (ltiple antihypertensive m)8.8 (edications were included in the pivotal clinical trials for )]TJ 0.0004 Tc -0.0004 Tw T* (VIAGRA. In a separate drug interaction study, wh)Tj 0.0002 Tc -0.0002 Tw 20.21 0 Td [(en am)8 (lodipine, 5 m)8 (g or 10 m)8 (g, and VIAGRA, )]TJ 0.0008 Tc -0.0008 Tw -20.21 -1.165 Td [(100 m)8.6 (g)0.8 ( were orally adm)8.6 (i)-1.4 (nistered concom)8.6 (itantly to hypertensive patients m)8.6 (ean additional blood )]TJ 0.0007 Tc -0.0007 Tw 0 -1.18 TD [(pressure reduction of 8 m)8.5 (m)8.5 (H)2.9 (g systolic and 7 m)8.5 (m)8.5 (H)2.9 (g diastolic were noted \(see )]TJ /TT1 1 Tf -0.0006 Tc 0 Tw 31.42 0 Td (Drug )Tj 0.0006 Tc -31.42 -1.18 Td (Interactions)Tj /TT0 1 Tf 0.001 Tc 5.175 0 Td (\).

Usual Adult Dose for Erectile Dysfunction

)]TJ 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(Patients on m)8.8 (u)1 (ltiple antihypertensive m)8.8 (edications were included in the pivotal clinical trials for )]TJ 0.0004 Tc -0.0004 Tw T* (VIAGRA. In a separate drug interaction study, wh)Tj 0.0002 Tc -0.0002 Tw 20.21 0 Td [(en am)8 (lodipine, 5 m)8 (g or 10 m)8 (g, and VIAGRA, )]TJ 0.0008 Tc -0.0008 Tw -20.21 -1.165 Td [(100 m)8.6 (g)0.8 ( were orally adm)8.6 (i)-1.4 (nistered concom)8.6 (itantly to hypertensive patients m)8.6 (ean additional blood )]TJ 0.0007 Tc -0.0007 Tw 0 -1.18 TD [(pressure reduction of 8 m)8.5 (m)8.5 (H)2.9 (g systolic and 7 m)8.5 (m)8.5 (H)2.9 (g diastolic were noted \(see )]TJ /TT1 1 Tf -0.0006 Tc 0 Tw 31.42 0 Td (Drug )Tj 0.0006 Tc -31.42 -1.18 Td (Interactions)Tj /TT0 1 Tf 0.001 Tc 5.175 0 Td (\). )Tj 0 Tc -5.175 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD (The safety of VIAGRA is unknown in patients with bleeding disorders and \ patients with active )Tj 0.001 Tc -0.001 Tw T* (peptic ulceration. )Tj 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(VIAGRA should be used with caution in patients with anatom)8.3 (ical deform)8.3 (ation of the penis \(such )]TJ 0.0008 Tc -0.0008 Tw T* (as angulation, cavernosal fibrosis or Peyronie\222s disease\), or in pat\ ients who have conditions )Tj 0.0009 Tc -0.0009 Tw T* [(which m)8.7 (ay predispose them)8.7 ( to priapism)8.7 ( \(such as sickle cell anem)8.7 (ia, m)8.7 (u)0.9 (ltiple m)8.7 (y)0.9 (elom)8.7 (a, or )]TJ 0 Tw T* [(leukem)8.7 (i)-1.3 (a\). )]TJ 0 Tc T* ( )Tj 0.0003 Tc -0.0003 Tw T* [(The safety and efficacy of com)8.1 (binations of)]TJ 0.0006 Tc -0.0006 Tw 17.16 0 Td [( VIAGRA with other treatm)8.4 (e)-0.6 (nts for erectile )]TJ 0.0005 Tc -0.0005 Tw -17.16 -1.165 Td (dysfunction have not been studied.

Drugs you should not use with sildenafil

Therefore, th)Tj 0.0006 Tc -0.0006 Tw 19.405 0 Td [(e use of such com)8.4 (b)0.6 (inations is not recom)8.4 (m)8.4 (e)-0.6 (nded. )]TJ 0 Tc 0 Tw -19.405 -1.165 Td ( )Tj 0.0004 Tc -0.0004 Tw T* [(In hum)8.2 (ans, VIAGRA has no effect on bleeding tim)8.2 (e when taken alone or with aspirin. )]TJ 0.0002 Tc -0.0002 Tw 17.72 0 Td [(The com)8 (bination of heparin and VIAGRA had an )]TJ 0.001 Tc -0.001 Tw -17.72 -1.165 Td [(additive ef)4 (f)4 (ect sildenafil gel on bleeding tim)8.8 (e in the anesthetized rabbit, but this interaction has not been )]TJ 0.0006 Tc -0.0006 Tw T* [(studied in hum)8.4 (ans. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0007 Tc -0.0007 Tw 0 -1.18 TD (Information for Patients )Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.155 TD (Physicians should discuss with patients the c)Tj 0.0004 Tc -0.0004 Tw (ontraindication of VIAGRA with regular and/or )Tj 0.0011 Tc -0.0011 Tw 0 -1.165 TD [(interm)8.9 (ittent use of)4.1 ( organic nitrates. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0006 Tc -0.0006 Tw T* [(Physicians should advise patients of the potential for VIAGRA to augm)8.4 (ent the blood pressure )]TJ T* [(lowering effect of alpha-blockers and anti-hypertensive m)8.5 (edications. )Tj 0 Tc -5.175 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD (The safety of VIAGRA is unknown in patients with bleeding disorders and \ patients with active )Tj 0.001 Tc -0.001 Tw T* (peptic ulceration. )Tj 0 Tc 0 Tw T* ( )Tj 0.0005 Tc -0.0005 Tw T* [(VIAGRA should be used with caution in patients with anatom)8.3 (ical deform)8.3 (ation of the penis \(such )]TJ 0.0008 Tc -0.0008 Tw T* (as angulation, cavernosal fibrosis or Peyronie\222s disease\), or in pat\ ients who have conditions )Tj 0.0009 Tc -0.0009 Tw T* [(which m)8.7 (ay predispose them)8.7 ( to priapism)8.7 ( \(such as sickle cell anem)8.7 (ia, m)8.7 (u)0.9 (ltiple m)8.7 (y)0.9 (elom)8.7 (a, or )]TJ 0 Tw T* [(leukem)8.7 (i)-1.3 (a\). )]TJ 0 Tc T* ( )Tj 0.0003 Tc -0.0003 Tw T* [(The safety and efficacy of com)8.1 (binations of)]TJ 0.0006 Tc -0.0006 Tw 17.16 0 Td [( VIAGRA with other treatm)8.4 (e)-0.6 (nts for erectile )]TJ 0.0005 Tc -0.0005 Tw -17.16 -1.165 Td (dysfunction have not been studied. Therefore, th)Tj 0.0006 Tc -0.0006 Tw 19.405 0 Td [(e use of such com)8.4 (b)0.6 (inations is not recom)8.4 (m)8.4 (e)-0.6 (nded. )]TJ 0 Tc 0 Tw -19.405 -1.165 Td ( )Tj 0.0004 Tc -0.0004 Tw T* [(In hum)8.2 (ans, VIAGRA has no effect on bleeding tim)8.2 (e when taken alone or with aspirin.

• Alcohol can increase the risk of side effects from sildenafil.
• Taking sildenafil does not protect against sexually transmitted infections.
• Patients should inform their doctor of all medications they take.
• Sildenafil may cause a drop in blood pressure in some cases.

)]TJ 0.0002 Tc -0.0002 Tw 17.72 0 Td [(The com)8 (bination of heparin and VIAGRA had an )]TJ 0.001 Tc -0.001 Tw -17.72 -1.165 Td [(additive ef)4 (f)4 (ect sildenafil gel on bleeding tim)8.8 (e in the anesthetized rabbit, but this interaction has not been )]TJ 0.0006 Tc -0.0006 Tw T* [(studied in hum)8.4 (ans.

Overdose/Missed Dose

Antiretroviral Agents

)]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0007 Tc -0.0007 Tw 0 -1.18 TD (Information for Patients )Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.155 TD (Physicians should discuss with patients the c)Tj 0.0004 Tc -0.0004 Tw (ontraindication of VIAGRA with regular and/or )Tj 0.0011 Tc -0.0011 Tw 0 -1.165 TD [(interm)8.9 (ittent use of)4.1 ( organic nitrates.

Related/similar drugs

Tadalis Sx

)]TJ 0 Tc 0 Tw T* ( )Tj 0.0006 Tc -0.0006 Tw T* [(Physicians should advise patients of the potential for VIAGRA to augm)8.4 (ent the blood pressure )]TJ T* [(lowering effect of alpha-blockers and anti-hypertensive m)8.5 (edications. Concom)8.5 (itant )]TJ 0.0005 Tc -0.0005 Tw T* [(adm)8.3 (i)-1.7 (nistration of VIAGRA and an alpha-blocker m)8.3 (a)-0.7 (y lead to sym)8.3 (p)0.5 (tom)8.3 (a)-0.7 (tic hypotension in som)8.3 (e)-0.7 ( )]TJ 0.0006 Tc -0.0006 Tw T* [(patients.

Warnings Related To Cenforce Medicine

Therefore, inhibitors of these isoenzym)8.5 (es )]TJ 0.001 Tc -0.001 Tw 0 -1.165 TD [(m)8.8 (ay reduce sildenafil clearance. )]TJ 0 Tc 0 Tw T* ( )Tj /TT2 1 Tf 0.0008 Tc -0.0008 Tw 0 -1.18 TD (In vivo)Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw 2.865 0 Td ( studies:)Tj /TT0 1 Tf 3.535 0 Td [( Cim)8.5 (etidine \(800 m)8.5 (g)0.7 (\), a nonspecific CYP inhibitor, caused a 56% increase in )]TJ -6.4 -1.165 Td [(plasm)8.4 (a)-0.6 ( sildenafil concentrations when coadm)8.4 (i)-1.6 (nistered with VIAGRA \(50 m)8.4 (g)0.6 (\) to healthy )]TJ 0.0009 Tc 0 Tw 0 -1.165 TD (volunteers. )Tj 0 Tc T* ( )Tj 0.0001 Tc -0.0001 Tw T* [(W)8.9 (hen a single 100 m)7.9 (g dose of VIAGRA was adm)7.9 (i)]TJ 0.0008 Tc -0.0008 Tw 20.335 0 Td [(nistered with erythrom)8.6 (ycin, a specific )]TJ 0.0007 Tc -0.0007 Tw -20.335 -1.165 Td [(CYP3A4 inhibitor, at steady state \(500 m)8.5 (g)0.7 ( bid for 5 days\), there was a 182% increase in )]TJ T* [(sildenafil system)8.5 (ic exposure \(AUC\). In addition, in a study perform)8.5 (ed in healthy m)8.5 (ale )]TJ T* [(volunteers, coadm)8.5 (i)-1.5 (nistration of the HIV protease i)-1.1 (nhibitor saquinavir, also a CYP3A4 inhibitor, )]TJ T* [(at steady state \(1200 m)8.5 (g)0.7 ( tid\) with VIAGRA \(100 m)8.5 (g)0.7 ( single dose\) resulted in a 140% increase in )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 312 0 obj <>>>/Resources 325 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 313 0 obj <>>>/Resources 327 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 327 0 obj <> endobj 328 0 obj <> endobj 326 0 obj <>stream /This label may not be the latest approved by FDA.

More common

For current labeling information, please visit endstream endobj 325 0 obj <> endobj 329 0 obj <> endobj 324 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 311 0 obj <> endobj 306 0 obj <>stream q 1 0 0 1 -8.008606 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.008606 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.9914 47.6228 Tm ( )Tj 19 -0.005 Td (12)Tj 0.0008 Tc -0.0008 Tw -19 54.94 Td [(- In those patients already taking an optim)8.6 (ized dose of a PDE5 inhibitor, alpha-blocker therapy )]TJ 0 -1.165 TD [(should be initiated at the lowest dose. Stepwise increase in alpha-block\ er dose m)8.6 (ay be associated )]TJ 0.0005 Tc -0.0005 Tw T* (with further lowering of blood pressure when taking a PDE5 inhibitor. )Tj T* [(- Safety of com)8.3 (b)0.5 (ined use of PDE5 inhibitors and alpha-blockers m)8.3 (a)-0.7 (y be affected by other )]TJ 0.0009 Tc -0.0009 Tw T* [(variables, including intravascular volum)8.7 (e depletion and other anti-hypertensive drugs. )]TJ 0 Tc 0 Tw T* ( )Tj 0.0007 Tc -0.0007 Tw T* [(Viagra has system)8.5 (ic vasodilatory properties and m)8.5 (ay augm)8.5 (ent the blood pressure lowering effect )]TJ 0.0009 Tc -0.0009 Tw sildenafil tables T* [(of other anti-hypertensive m)8.7 (edications. Therefore, when VIAGRA is co-adm)8.4 (inistered with alpha-blockers, patients should be )]TJ 0.001 Tc -0.001 Tw T* (stable on alpha-blocker therapy prior to in)Tj 0.0001 Tc -0.0001 Tw 16.865 0 Td [(itiating VIAGRA treatm)7.9 (e)-1.1 (nt and sildenafil pfizer 100g VIAGRA should be )]TJ 0.001 Tc -0.001 Tw -16.865 -1.165 Td (initiated at the lowest dose.

)Tj 0 Tc 0 Tw T* ( )Tj 0.0009 Tc -0.0009 Tw T* (Physicians should discuss with patients the potential cardiac risk of se\ xual activity in patients )Tj 0.0008 Tc -0.0008 Tw T* [(with preexisting cardiovascular risk factors.

Patients who experience sy\ m)8.6 (p)0.8 (tom)8.6 (s \(e.g., angina )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 308 0 obj <>>>/Resources 331 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.

) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 309 0 obj <>>>/Resources 333 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 333 0 obj <> endobj 334 0 obj <> endobj 332 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 331 0 obj <> endobj 335 0 obj <> endobj 330 0 obj <>stream /This label may not be the latest approved by FDA.

What other drugs will affect sildenafil?

Concom)8.5 (itant )]TJ 0.0005 Tc -0.0005 Tw T* [(adm)8.3 (i)-1.7 (nistration of VIAGRA and an alpha-blocker m)8.3 (a)-0.7 (y lead to sym)8.3 (p)0.5 (tom)8.3 (a)-0.7 (tic hypotension in som)8.3 (e)-0.7 ( )]TJ 0.0006 Tc -0.0006 Tw T* [(patients. Therefore, when VIAGRA is co-adm)8.4 (inistered with alpha-blockers, patients should be )]TJ 0.001 Tc -0.001 Tw T* (stable on alpha-blocker therapy prior to in)Tj 0.0001 Tc -0.0001 Tw 16.865 0 Td [(itiating VIAGRA treatm)7.9 (e)-1.1 (nt and sildenafil pfizer 100g VIAGRA should be )]TJ 0.001 Tc -0.001 Tw -16.865 -1.165 Td (initiated at the lowest dose. )Tj 0 Tc 0 Tw T* ( )Tj 0.0009 Tc -0.0009 Tw T* (Physicians should discuss with patients the potential cardiac risk of se\ xual activity in patients )Tj 0.0008 Tc -0.0008 Tw T* [(with preexisting cardiovascular risk factors. Patients who experience sy\ m)8.6 (p)0.8 (tom)8.6 (s \(e.g., angina )]TJ ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 308 0 obj <>>>/Resources 331 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 309 0 obj <>>>/Resources 333 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 333 0 obj <> endobj 334 0 obj <> endobj 332 0 obj <>stream /This label may not be the latest approved by FDA.

Sildenafil Tablets for ED

For current labeling information, please visit endstream endobj 331 0 obj <> endobj 335 0 obj <> endobj 330 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 307 0 obj <> endobj 302 0 obj <>stream q 1 0 0 1 -8.141602 -1.487244 cm 0 0 612 792 re W n 1 0 0 1 8.141602 1.487244 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.8584 48.0128 Tm ( )Tj 19 -0.005 Td (11)Tj /C2_0 1 Tf -19 54.875 Td <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw 1.04 0 Td [(Patients with resting hypotension \(BP )-3.4 (<90/50\) or hypertension \(BP >170/110\); )]TJ 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf 0 -1.23 TD <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td (Patients with cardiac failure or coronary artery disease causing unstabl\ e angina; )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf T* <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td [(Patients with retinitis pigm)8.7 (entosa \(a m)8.7 (i)-1.3 (nority of)3.9 ( these patients have genetic disorders of)3.9 ( )]TJ 0 -1.165 TD (retinal phosphodiesterases\). )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj 0.0008 Tc -0.0008 Tw T* [(Prolonged erection greater than 4 hours and priapism)6.7 ( \(painful erections greater than 6 hours in )]TJ 0.0006 Tc -0.0006 Tw T* [(duration\) have been reported infrequently since m)8.4 (a)-0.6 (rket approval of VIAGRA. In the event of an )]TJ 0.0009 Tc -0.0009 Tw T* [(erection that persists longer than 4 hours, the patient should seek im)8.7 (m)8.7 (ediate m)8.7 (edical assistance. For current labeling information, please visit endstream endobj 307 0 obj <> endobj 302 0 obj <>stream q 1 0 0 1 -8.141602 -1.487244 cm 0 0 612 792 re W n 1 0 0 1 8.141602 1.487244 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.8584 48.0128 Tm ( )Tj 19 -0.005 Td (11)Tj /C2_0 1 Tf -19 54.875 Td <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw 1.04 0 Td [(Patients with resting hypotension \(BP )-3.4 (<90/50\) or hypertension \(BP >170/110\); )]TJ 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf 0 -1.23 TD <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td (Patients with cardiac failure or coronary artery disease causing unstabl\ e angina; )Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj /C2_0 1 Tf T* <0078>Tj /TT1 1 Tf 0.46 0 Td ( )Tj /TT0 1 Tf 0.0009 Tc -0.0009 Tw 1.04 0 Td [(Patients with retinitis pigm)8.7 (entosa \(a m)8.7 (i)-1.3 (nority of)3.9 ( these patients have genetic disorders of)3.9 ( )]TJ 0 -1.165 TD (retinal phosphodiesterases\).

• Be aware of the signs of adverse reactions like chest pain.
• Do not use sildenafil if you are taking medications for heart issues.
• The medication does not cause sexual arousal; stimulation is needed.
• Use only the prescribed dose, especially at high levels like 150 mg.

)Tj 0 Tc 0 Tw -1.5 -1.165 Td ( )Tj 0.0008 Tc -0.0008 Tw T* [(Prolonged erection greater than 4 hours and priapism)6.7 ( \(painful erections greater than 6 hours in )]TJ 0.0006 Tc -0.0006 Tw T* [(duration\) have been reported infrequently since m)8.4 (a)-0.6 (rket approval of VIAGRA. In the event of an )]TJ 0.0009 Tc -0.0009 Tw T* [(erection that persists longer than 4 hours, the patient should seek im)8.7 (m)8.7 (ediate m)8.7 (edical assistance.